Novo Nordisk and Viatris have agreed to resolve a patent dispute over Novo's blockbuster weight-loss drugs Ozempic and Wegovy ...

Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo ...

NORTHAMPTON, MA / ACCESSWIRE / October 7, 2024 / Viatris Across all Viatris locations, we are committed to protecting contractors and visitors. They are covered by site-specific EHS policies and ...

Novo Nordisk ($NVO) and Viatris ($VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

In the phase 3b BATURA trial, Airsupra—a pressurized metered-dose inhaler containing albuterol and budesonide—significantly ...

"It could be big. I think it could be as big as some of the others we've gotten here," Anapol Weiss shareholder Kila Baldwin ...

The program is examining the effectiveness of a protocol meant to ensure safety for pilots and air traffic controllers on ...

Novo Nordisk and Mylan Pharmaceuticals, now part of Viatris, have settled their patent dispute over Novo’s blockbuster ...

(CVS) just announced it was considering a breakup. Why is that important? Spinoffs are one of the best-kept investment ...

Duckhorn (NAPA) to be acquired by Butterfly Equity in $1.95B all-cash deal, with shares jumping over 100% premarket.

The Global Drug Device Combination Products Market is projected to reach USD 174.4 billion in 2024 which is further ...